To evaluate the long-term safety of RGL-193 capsid injection in patients with primary Parkinson's disease over 5 years

An open-label, observational, long-term follow-up study evaluating the safety and efficacy of RGL-193 capsid injection in patients with primary Parkinson's disease over 5 years

Inclusion Criteria:

1. Subjects who have previously participated in RGL-193-related studies and have received RGL-193 treatment；
2. Those who voluntarily participate in this trial and sign a written informed consent form -

Exclusion Criteria:

None

-

Patients with mid-to-late stage Parkinson's disease